News Center
News Type
Great news! Qingfeng Pharmaceutical's Enzalutamide API and Soft Capsules are approved for marketing in the United States
On September 26, the enzalutamide API and soft capsule developed by Qingfeng Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for marketing by the U.S. Food and Drug Administration (FDA).
Big news! Enzalutamide API successfully passed FDA on-site audit
From August 21 to 25, 2023, the U.S. Food and Drug Administration (FDA) conducted a five-day on-site audit of Qingfeng Pharmaceutical's enzalutamide API and the company's overall production quality management system. FDA Inspector Ms. Michele Glendenning gave a formal opinion that the inspection passed.
Rabeprazole sodium enteric-coated tablets were approved, A new member of the Qingfeng digestive family
On August 3, the NMPA approved the marketing of Rabeprazole Sodium Enteric-coated Tablets developed by Shanxiang Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group. This is the second proton pump inhibitor approved by Qingfeng Pharmaceutical Group in the field of digestion.
Qingfeng was listed as the "best industrial enterprise in China's pharmaceutical R & D product line"
On August 1, 2021 (the 38th) national pharmaceutical industry information annual conference was grandly opened in Jinan, Shandong Province. The conference officially released the list of the best industrial enterprises in China's pharmaceutical R&D product line in 2021. Qingfeng Pharmaceutical Group was listed on the list with its outstanding R&D and innovation driving force over the years!
Qingfeng won the bid for the fourth batch of national volume based procurement for two products
On February 3, Shanghai Yangguang Pharmaceutical Purchasing Network officially released the bidding results of fourth batch of national volume based procurement. Jiangxi Shanxiang Pharmaceutical Co., Ltd. (a subsidiary of Qingfeng Pharmaceutical Group) stood out for two products and successfully won the bid, namely Bangkaxin® Es omeprazole magnesium enteric-coated Tablets, and Ligesitai® Sorafenib tosylate tablets.
Sorafenib was approved as the first generic in China
The Class 4 chemical generic Sorafenib tosylate tablets (trade name: Ligesitai®) developed by Jiangxi Shanxiang Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, were approved by the National Medical Products Administration on August 5, 2020. NMPA).
